menu search

RIGL / Rigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call Transcript

Rigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Dolly Vance - EVP, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Wolfgang Dummer - EVP and Chief Medical Officer Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and Chief Financial Officer Caroline Piatek - Associate Professor of Clinical Medicine Conference Call Participants Eun Yang - Jefferies Gary Nachman - BMO Capital Markets Kalpit Patel - B. Riley Securities Joseph Pantginis - H.C. Read More
Posted: May 3 2022, 23:01
Author Name: Seeking Alpha
Views: 103135

RIGL News  

Rigel to Participate in Upcoming September Investor Conferences

By PRNewsWire
August 30, 2023

Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the compa more_horizontal

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 1, 2023

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Co more_horizontal

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 1, 2023

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares t more_horizontal

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 2, 2023

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares t more_horizontal

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability

By Seeking Alpha
April 27, 2023

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability. more_horizontal

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

By PRNewsWire
April 25, 2023

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first more_horizontal

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 7, 2023

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Cou more_horizontal

Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates

By Zacks Investment Research
March 7, 2023

Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold cl more_horizontal


Search within

Pages Search Results: